Commercializing the first da Vinci surgical robot: Lessons you need to know

Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them! Daniel Hawkins is the President and CEO of Shockwave Medical. He began his career in marketing and business development roles for Advanced Cardiovascular Systems, otherwise known as ACS, which is now part of Abbott Vascular. Following ACS, he held senior roles in general management, marketing, and business development with a number of private and public companies. Daniel started the marketing department at Intuitive Surgical where he guided product feature development for the da Vinci Surgical Robot and developed key foundational marketing strategies for the company. He has also held senior leadership and/or founder roles with Endologix and Calibra Medical, which is now part of J&J. Daniel has an MBA from Stanford, a BS in economics from Wharton, and is a named inventor on over 100 patents and applications. Here are a few of the things we’re going to learn in this interview with Daniel: How his early upbringing gave rise to his entrepreneurial spirit. Why focusing on pain killers is imperative for medtech startups. Daniel’s early experiences at Intuitive Surgical and some of the most important lessons he learned commercializing the first surgical robot. A question every medtech entrepreneur should ask themselves, “Does your product have natural pull?&rd...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Blog medsider Source Type: news

Related Links:

RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Chronic pain is an enigma for both pain doctors and their patients: difficult to understand (as everyone’s pain is different), challenging to treat effectively, and frustrating to live with. Desperate patients sometimes turn to drastic and irreversible surgical procedures, like amputating nerves to relieve pain, and unfortunately even those procedures may fail to provide the hoped-for results. Fortunately there have been great strides in research related to pain perception and our nervous system’s reaction to various pain treatments, and we’ve been able to develop novel devices that provide many people wi...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Back Pain Pain Management Source Type: blogs
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us. So without further ado, here are the 20 companies that made the cut: 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us. So without further ado, here are the 20 companies that made the cut: 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Conclusion: In this patient case, clinical findings along with a comprehensive family and personal history, ruled out a musculoskeletal condition and implicated a vascular condition. PMID: 31661344 [PubMed - as supplied by publisher]
Source: Physiotherapy Theory and Practice - Category: Physiotherapy Authors: Tags: Physiother Theory Pract Source Type: research
Eckstein HH, Ferraresi R, Gambhir R, Garguilo M, Geraghty P, Goode S, Gray B, Guo W, Gupta PC, Hinchliffe R, Jetty P, Komori K, Lavery L, Liang W, Lookstein R, Menard M, Misra S, Miyata T, Moneta G, Munoa Prado JA, Munoz A, Paolini JE, Patel M, Pomposelli F, Powell R, Robless P, Rogers L, Schanzer A, Schneider P, Taylor S, De Ceniga MV, Veller M, Vermassen F, Wang J, Wang S, GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS) Abstract GUIDELINE SUMMARY: Chronic limb-threatening ischemi...
Source: PubMed: Eur J Vasc Endovasc ... - Category: Surgery Authors: Tags: Eur J Vasc Endovasc Surg Source Type: research
I was in suburban Chicago recently one morning, hoping to get something to eat for breakfast. I’d heard that the Panera chain was now serving breakfast that you could order any way you wanted. It’s called “Panera Bread,” but I thought I’d give it a try, as I’ve safely consumed their salads in past. At the counter, I placed my order for 3 eggs over easy, sausage, and bacon—not perfect, given our inability to scrutinize foods and ingredients in such places, but I was willing to try. Obviously, I turned down the breads/toasts that were included. The middle-aged Hispanic woman behind t...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: Wheat Belly diabetes grain-free grains Inflammation sugar undoctored Source Type: blogs
A 60-something presented with hypotension, bradycardia, chest pain and back pain.She had a h/o aortic aneurysm, aortic insufficiency, peripheral vascular disease, and hypertension.  She had a mechanical aortic valve.  She was on anti-hypertensives including atenolol, and on coumadin, with an INR of 2.3. She was ill appearing.  BP was 70/49, pulse 60.A bedside echo showed good ejection fraction and normal right ventricle and no pericardial fluid. Here is the initial ECG:What do you think?This ECG actually looks like a left main occlusion (which rarely presents to the ED alive):  ST Elevation in...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
The excitement around bioresorbable stents might have calmed down considerably over the last year, but all that could change. Reva Medical, a San Diego, CA-based company is bringing the technology back into the spotlight with a recent approval. The company has received a CE mark for its Motiv bioresorbable scaffold to be used for the treatment of below-the-knee (BTK) peripheral artery disease (PAD). The CE mark is also significant for Reva because it marks the company’s entry into the PAD space. The company already has CE mark for its Fantom bioresorbable scaffold, which treats patients for coronary arter...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news
More News: Angioplasty | Back Pain | Baloon Angioplasty | Biology | Blogging | Calcium | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemistry | Economics | Environmental Health | Heart | Jobs | Laparoscopy | Learning | Legislation | Lessons | Marketing | Medical Devices | Men | Minimally Invasive Surgery | Orthopaedics | Pain | Pain Management | Peripheral Vascular Disease (PVD) | Physics | Primary Care | Science | Small Businesses | Study | Ultrasound | Universities & Medical Training | Venture Capital | Vitamins